Traws Pharma (TRAW, Financial) has shared promising results from a significant clinical study on rigosertib, an oncology asset they are looking to develop further with commercial partners. The details, published in the British Journal of Dermatology, reveal the first clinical trial of an experimental cancer drug targeting RDEB-associated squamous cell carcinoma (SCC), a rare and complex genetic disorder. The study showed an impressive 80% overall response rate, with half of the evaluated participants experiencing complete responses.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.